Brensocatib is an orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), with potential anti-inflammatory activity. Upon oral administration, brensocatib reversibly binds to and inhibits the activity of DPP1, thereby inhibiting the activation of neutrophil serine proteases (NSPs), including neutrophil elastase (NE), during neutrophil maturation. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include 1, 4-Oxazepine-2-carboxamide, N-((1S)-1-cyano-2-(4-(2, 3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)phenyl)ethyl)hexahydro- and Brinsupri. Its PubChem CID is 118253852.
Brensocatib
| CAS No | 1802148-05-5 |
|---|---|
| Molecular Formula | C23H24N4O4 |
| Molecular Weight | 420.5 g/mol |
| Synonyms | (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Brensocatib is an orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), with potential anti-inflammatory activity.
The listed CAS number is 1802148-05-5.
The listed molecular formula is C23H24N4O4.
The listed molecular weight is 420.5 g/mol.
(2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide.
The source lists 1, 4-Oxazepine-2-carboxamide, N-((1S)-1-cyano-2-(4-(2, 3-dihydro-3-methyl-2-oxo-5-benzoxazolyl)phenyl)ethyl)hexahydro- and Brinsupri.